Stay updated on Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page.

Latest updates to the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page
- Check5 days agoChange DetectedAdded IPD sharing information for the study, including Plan Description, access criteria, time frame, and the IPD Sharing URL. The update also includes policy language from Bristol-Myers Squibb about providing access to anonymized participant data to qualified researchers.SummaryDifference0.5%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, indicating a software version update. This change updates the page’s revision metadata rather than altering study content or data.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe page revision changed from v3.6.4 to v3.6.5, indicating a new version of the page has been deployed. This reflects version control activity rather than substantive content changes to the study details.SummaryDifference0.0%

- Check55 days agoChange DetectedA new revision label v3.6.4 was added and the prior v3.6.3 revision was removed.SummaryDifference0.0%

- Check77 days agoChange DetectedThe revision tag on the page was updated from v3.6.2 to v3.6.3, indicating a new version of the page materials. This reflects a minor update to the page's documentation or release notes rather than content changes.SummaryDifference0.0%

- Check84 days agoChange DetectedThe page's revision label changed from v3.6.0 to v3.6.2, indicating a new version of the page has been released. This reflects a deployment update rather than a substantive change to study content or functionality.SummaryDifference0.0%

Stay in the know with updates to Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Efficacy in Active Psoriatic Arthritis Clinical Trial page.